KDR and cancer: Among those, Sorafenib inhibits multiple receptor tyrosine kinases, including Rapidly Accelerated Fibrosarcoma (RAF) kinase, VEGFR-2, VEGFR-3 and PDGF receptor β (PDGFR β), and thereby interferes with angiogenesis, tumor invasion and metastasis on multiple levels and is clinically effective against severe cancers with poor prognosis such renal cell carcinoma and hepatocellular cancer [65].